JPRN-jRCT2073220083进行中（未招募）3 期
A Phase 3 single-arm multicenter study of FF-31501 in meniscus tear patients
Sakurai Tsutomu0 个研究点目标入组 18 人开始时间: 2023年1月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with suspected meniscus flap tear
- •2.Patients with knee pain
- •3.Patients with one or more of the following symptoms
- •Feeling stuck in the knee
- •Instability of the knee
- •Knee range of motion impairment
- •Knee joint edema
排除标准
- •1.Patients with poor knee alignment
- •2.Patients who underwent meniscus surgery or platelet rich plasma therapy
- •3.Patients with or history of knee ligament injury
- •4.Diabetic patients with poor glycemic control
- •5.Patients with the following complications and poor general condition
- •Severe cardiovascular disease
- •Severe liver disease
- •Severe renal dysfunction
- •Severe anemia
- •uncontrolled mental illness
- •Other diseases for which sudden change or worsening of symptoms can be expected during study participation
- •6.Patients who are pregnant or possibly pregnant and/or breast-feeding, or patients planning to become pregnant during the study period
研究者
相似试验
招募中
1 期
Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856Crohn's diseaseCTIS2022-502050-14-00Abbvie Deutschland GmbH & Co. KG114
招募中
不适用
A Single-Center, Single-Cohort Study of FF-37101 for Bone Formation in the Maxillomandibular RegioNL-OMON24676Fujifilm Manufacturing Europe BV30
招募中
不适用
A Single-Center, Single-Cohort Study of FF-37101 for Bone Formation in the Maxillomandibular RegioNL-OMON55475FUJIFILM Manufacturing Europe BV28
进行中（未招募）
3 期
A phase III study of FPF3401HyposelenemiaJPRN-jRCT2031220210rabe Hiromi53
进行中（未招募）
不适用
Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer - n.a.MedDRA version: 9.1Level: LLTClassification code 10033162Term: Ovarian epithelial cancer stage IIMedDRA version: 9.1Level: LLTClassification code 10033163Term: Ovarian epithelial cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10033164Term: Ovarian epithelial cancer stage IVMedDRA version: 9.1Level: LLTClassification code 10033161Term: Ovarian epithelial cancer stage IEpithelial Ovarian CancerEUCTR2006-004484-54-DEFresenius Biotech GmbH